Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.CERU · Entity 7799 | Principal Accounting Officer | January 05, 2017 | January 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date January 05, 2017 · Filed January 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-04 | Direct | 5,000 |
Reported balance
After 2017-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-05 · Grant · Acquired 5,000 · Balance 5,000 F1: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-04 | Direct | 5,000 |
Reported balance
After 2017-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-05 · Grant · Acquired 5,000 · Balance 5,000 F1: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2027-01-04 | Direct | 50,000 |
Reported balance
After 2017-01-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-05 · Grant · Acquired 50,000 · Balance 50,000 F2: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017.
F2: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2017 Filed Jan 9, 2017 22:16 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002981 · doc4.xml · derivative · entry 3 ONeill James E · CIK 0001307183 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 22:16 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002981 · doc4.xml · derivative · entry 2 ONeill James E · CIK 0001307183 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 22:16 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-17-002981 · doc4.xml · derivative · entry 1 ONeill James E · CIK 0001307183 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.